22 December 2025VideosBiotechDirk Buehler, Maiwald

WATCH: “Try and see” – an underestimated standard for obviousness before the EPO?

Dirk Buehler, Maiwald, discusses how the “try and see” standard is applied before the EPO and its relevance in pharma and biotech cases.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Biotech

Amgen hit with lawsuit over its proposed Opdivo biosimilar

16 September 2026 BMS is stepping up its defence of its blockbuster cancer drug Opdivo as Amgen moves closer to the biosimilar market.

Biotech

Pfizer strikes $10.5 billion oncology deal with Chinese biotech

4 June 2026 The deal gives Pfizer access to 12 early-stage oncology programmes and marks the latest in a growing wave of high-value licensing agreements between Big Pharma and Chinese biotechs.

Biotech

Gilead to pay up to $5bn for antibody-drug conjugates push

8 April 2026 The acquisition of Munich-based biotech gives Gilead ownership of proprietary ADCs tech at a time when pharma and biotech companies are racing to secure next-generation cancer treatments.

More features

US firm hires litigation pro whose clients include Pfizer, Medtronic

Oxford Nanopore scores urgent injunction at UPC in DNA sequencing fight

Leading European patent litigator to join Carpmaels & Ransford

Non-profit sues Cambrex over anticancer drug manufacturing trade secrets

Amgen hit with lawsuit over its proposed Opdivo biosimilar

Australian biotech sues Grail over multi-cancer blood test

10x Genomics wins latest round in Parse patent dispute

Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win

WATCH: “Try and see” – an underestimated standard for obviousness before the EPO?

More on this story

Editor's picks

Editor's picks

More features